SSRIs and Teen Suicide Risk: Meta-Analysis Review
This paper reviews a systematic meta-analysis examining the relationship between selective serotonin reuptake inhibitors (SSRIs) and suicide risk across different age groups. Drawing on the findings of Barbui, Esposito, and Cipriani (2009), the paper explains how the study analyzed data from over 200,000 patients across multiple observational and case-control studies. It situates the research within the context of an earlier FDA review of antidepressant trials, discusses the quantitative methodology employed, and summarizes the age-stratified findings. The paper also highlights two specific SSRIs — paroxetine and venlafaxine — identified as posing elevated risk for younger patients, and notes the clinical recommendations made by the study's authors.
- Introduction: SSRIs and Age-Related Suicide Risk: SSRIs carry age-dependent suicide risk for patients
- Quantitative Methodology of the Meta-Analysis: Study uses statistics from 200,000+ patient dataset
- Background: The FDA Antidepressant Trials: FDA trials motivated broader suicidality analysis
- Literature Search and Avoiding Publication Bias: Multilingual search strategy minimized publication bias
- Findings and Clinical Recommendations: Paroxetine and venlafaxine flagged; monitoring recommended
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper moves logically from background context (the FDA trials) to methodology to results, giving readers a clear narrative arc through a complex quantitative study.
- It accurately distinguishes between quantitative and qualitative aspects of the research, demonstrating methodological awareness appropriate for the assignment.
- Direct quotations from the source studies are used judiciously to anchor analytical claims, rather than simply paraphrasing throughout.
Key academic technique demonstrated
The paper demonstrates source synthesis by situating one meta-analysis within the broader context of the FDA trials that motivated it. Rather than summarizing a single study in isolation, the writer connects the two bodies of research to show how the meta-analysis extends and refines earlier findings — a hallmark of literature-review thinking at the undergraduate level.
Structure breakdown
The paper opens with the central finding, then explains the study's methodology, traces its origins in the FDA research, evaluates its literature search practices, and closes with results and clinical recommendations. Each paragraph addresses a distinct analytical layer, keeping the discussion focused and progression clear throughout.
Introduction: SSRIs and Age-Related Suicide Risk
One of the leading treatments for depression is selective serotonin reuptake inhibitors (SSRIs); however, their effectiveness appears to be age-related. In a study titled "Selective Serotonin Reuptake Inhibitors and Risk of Suicide: A Systematic Review of Observational Studies," the authors assert that the effectiveness of these drugs depends on the age of the patient. Young patients aged 25 or younger showed an increased risk of suicide or suicide attempt, while patients aged 65 or older showed a reduced risk. The risk for those between the ages of 25 and 65 was found to be neutral.
Quantitative Methodology of the Meta-Analysis
This study was quantitative because it used data from other studies to calculate statistics related to the relationship between SSRI use and suicide. One of the defining features of a quantitative study is the use of statistics to present evidence in mathematical form. In their research, the authors "analyzed data from 6 observational cohort and 2 case-control studies representing over 200,000 patients…" ("Meta-analysis," 2009, p. 6). The authors also conducted statistical analyses on each of the individual studies to ensure that no random-effect sensitivity influenced their results. However, the authors acknowledged that "confounding by illness severity" — a typically qualitative concern — could not be excluded from their analysis, and they admitted that qualitative factors were not formally incorporated into their study ("Meta-analysis," 2009, p. 7).
Background: The FDA Antidepressant Trials
The authors undertook this study primarily to build on a review conducted by the U.S. Food and Drug Administration (FDA) of "372 randomized placebo-controlled trials" of antidepressants ("Meta-analysis," 2009, p. 5). In those trials, the FDA found an age-related risk of suicide among patients; however, the trials were not designed to account for the concept of "suicidality" — that is, the ideation, preparation, and attempts at suicide — only actual completed suicides. The authors sought to conduct a more comprehensive analysis of the relationship among age, SSRI use, and suicidality.
References
Barbui, C., Esposito, E., and Cipriani, A. (2009). Selective serotonin reuptake inhibitors and risk of suicide: A systematic review of observational studies. CMAJ, 180(3), 291–297. Retrieved from
Meta-analysis shows teen suicide risk nearly double for SSRIs. (May 2009). The Brown University Psychopharmacology Update, 20(5). Print.
Always verify citation format against your institution’s current style guide requirements.